Novo Nordisk A/S (NYSE:NVO) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lowered its position in Novo Nordisk A/S (NYSE:NVO) by 10.3% in the third quarter, HoldingsChannel reports. The firm owned 147,376 shares of the company’s stock after selling 16,972 shares during the period. Oppenheimer & Co. Inc.’s holdings in Novo Nordisk A/S were worth $17,548,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Advisor OS LLC raised its holdings in Novo Nordisk A/S by 0.6% during the second quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock worth $1,994,000 after purchasing an additional 82 shares in the last quarter. Cascade Financial Partners LLC grew its position in shares of Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock worth $543,000 after acquiring an additional 84 shares during the last quarter. Novare Capital Management LLC grew its position in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after acquiring an additional 85 shares during the last quarter. AA Financial Advisors LLC grew its position in shares of Novo Nordisk A/S by 3.2% during the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after acquiring an additional 86 shares during the last quarter. Finally, Steel Grove Capital Advisors LLC grew its position in shares of Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock worth $541,000 after acquiring an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded down $0.05 during midday trading on Wednesday, hitting $107.01. 313,452 shares of the stock were exchanged, compared to its average volume of 4,427,985. The stock has a market cap of $480.21 billion, a P/E ratio of 34.64, a PEG ratio of 1.32 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a 50 day moving average price of $120.23 and a 200-day moving average price of $130.08.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.